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Figure captions 1 
 2 
Fig. 1. Host-cell-mediated sequential enzymatic phosphorylation steps required for 3 
activating the nucleotide- and nucleoside-analogue reverse-transcriptase inhibitors 4 
(NRTIs) to the triphosphate moiety (Reproduced from Anderson et al.[17]). ABV = 5 
abacavir; AMPD = adenosine monophosphate deaminase; AMPK = adenosine 6 
monophosphate kinase (adenylate kinase); APT = adenosine phosphotransferase; 7 
CBV = carbovir; dCK = deoxycytidine kinase; dCMPK = deoxycytidine 8 
monophosphate kinase; ddA = 2',3'-dideoxyadenosine; ddI, = didanosine; DP, = 9 
diphosphate; d4T = stavudine; FTC = emtricitabine; gK = guanylate kinase; MP 10 
monophosphate; PMPA = tenofovir (PMPA DP is a triphosphate analogue); TFV = 11 
tenofovir; TP = triphosphate; ZDV = zidovudine; 3TC = lamivudine; 5'NDPK = 5' 12 
nucleoside diphosphate kinase; 5'NT = 5' nucleotidase.  13 
 14 
Fig. 2. Schematic representation of uptake and efflux transporters that may influence 15 
intracellular concentrations of antiretroviral drugs in peripheral blood cells. 16 
Transporters are named by gene and proteins (Adapted from Ford et al.[53] and 17 
updated[55-57]). OCT = Organic Cation Transporters, hCNT = Concentrative 18 
Nucleoside Transporter, ENT = Equilibrative Nucleoside Transporter, P-gp = P-19 
glycoprotein, MRP = Multidrug Resistance Protein, BCRP = Breast Cancer 20 
Resistance protein. 21 
 22 
 23 
 24 
 25 
 26 
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Abstract  1 
In patients infected by human immunodeficiency virus (HIV), the efficacy of highly 2 
active antiretroviral therapy (HAART) through the blockade of different steps of this 3 
retrovirus life-cycle is now well established.  As HIV is a retrovirus which replicates 4 
within the cells of the immune system, intracellular drug concentrations are important 5 
to determine antiretroviral efficacy and toxicity. Indeed, nucleoside reverse 6 
transcriptase inhibitors (NRTI), non nucleoside reverse transcriptase inhibitors 7 
(NNRTI), newly available integrase inhibitors and protease inhibitors (PI) act on 8 
intracellular targets. NRTIs are prodrugs that require intracellular anabolic 9 
phosphorylation to be converted into their active form: the triphosphorylated drug 10 
metabolite (NRTI-TP), half-life of which being longer than plasma half-life of the 11 
parent compound for most. Activity of intracellular kinases, expression of uptake 12 
transporters which may be dependent upon cell functionality or their activation state 13 
may greatly influence intracellular concentrations of NRTI-TP. In contrast, NNRTIs as 14 
well as PIs are not prodrugs and exert their activity by inhibiting directly enzyme 15 
targets. All PIs, are substrates of CYP3A, which explains most of them display poor 16 
pharmacokinetic properties with intensive pre-systemic first pass metabolism and 17 
short elimination half-lives. There are evidences that intracellular concentration of PIs 18 
depends on P-gp and/or other efflux transporters activity, which is modulated by 19 
genetic polymorphism and co-administration of drugs with inhibiting or inducing 20 
properties. Assaying adequately the intracellular concentrations of antiviral (ARVs) 21 
drugs is still a major technical challenge, together with the isolation and the counting 22 
of peripheral blood mononuclear cells (PBMCs). Furthermore, intracellular drug could 23 
be bound to cell membranes or proteins; the amount of intracellular ARV available for 24 
antiretroviral effectiveness is never measured which is a limitation of all published 25 
studies. In this review, we summarized the results of thirty-one articles that provided 26 
results of intracellular concentrations of ARVs in HIV-infected patients. Most studies 27 
also measured plasma concentrations but few of them studied the relationship 28 
between plasma and intracellular concentrations. For NRTIs, most studies could not 29 
established significant relationship between plasma and triphosphate concentrations. 30 
Only eight published studies reported an analysis of the relationships between 31 
intracellular concentrations and virological or immunological efficacy of antiretroviral 32 
drugs in HIV patients. In prospective studies well designed and with a reasonnable 33 
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number of patients, a significant correlation between virological efficacy and 1 
intracellular concentrations of NRTIs was found with no influence of plasma 2 
concentration. For PIs, the only prospectively design trial on lopinavir found both the 3 
influence of trough plasma and intracellular concentrations. ARVs are known to 4 
produce important adverse effects through their interferences with cellular 5 
endogenous processes. The relationship between intracellular concentrations of 6 
ARVs and their related toxicity were investigated in only four articles. For zidovudine, 7 
the relative strength of the association between haemoglobin decrease and plasma 8 
zidovudine compared to intracellular zidovudine-triphosphate is still unknown. 9 
Similarly, for efavirenz and neuropsychological disorder methodological differences 10 
penalize the comparison between studies. In conclusion, intracellular concentrations 11 
of ARVs play a major role in their efficacy and toxicity and are influenced by 12 
numerous factors. However the number of published clinical studies in that area is 13 
limited; most studies were small and not always adequately designed. In addition, 14 
standardization of assays and PBMC counts are warranted. Larger and prospectively 15 
designed clinical studies are needed to further investigate the links between 16 
intracellular concentrations of ARVs and clinical endpoints.  17 
 18 
 19 
 20 
21 
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1 Introduction 1 
Human Immunodeficiency Virus (HIV) is a retrovirus, which replicates within the cells 2 
of the immune system. The efficacy of highly active antiretroviral therapy (HAART), is 3 
now well established, and has provided extraordinary benefits to many patients with 4 
HIV infection.[1] The morbidity and mortality related to HIV infection have dramatically 5 
decreased in countries in which HAART has been available, turning HIV infection into 6 
a chronic manageable disease.[2] Life-long antiretroviral treatment seems necessary, 7 
as viral replication and loss of CD4 cells resume when HAART is interrupted. HAART 8 
regimens have shown some limitations, the major one being the failure to eradicate 9 
HIV even after several years of therapy. One of the reasons is that despite potent 10 
antiretroviral (ARV) treatment, compartments of replication-competent virus persist, 11 
suggesting that ARVs do not reach all the infected cells: however, there are no data 12 
to support this theorical assumption. This article will focus on pharmacologic 13 
principles that govern intracellular concentrations of antiretroviral drugs and on 14 
clinical studies which aimed at assessing whether intracellular concentrations of 15 
ARVs could be a useful parameter to predict efficacy or toxicity of antiretroviral drug 16 
regimen. 17 
The different steps of HIV replication are now well identified and understood. A 18 
number of antiretroviral drugs are now available and are grouped in five 19 
pharmacologic classes according to their mechanism of action. These drugs target 20 
essential receptors or enzymes at different steps of the life cycle of the virus and will 21 
block the production of infectious retroviral particles from the cell.[3] However virus 22 
eradication cannot be achieved with the available treatments because of the pool of 23 
latently infected CD4 cells.[4]  24 
HAART is the standard of care to avoid selection of viral mutations. Selection of 25 
drugs for treatment naïve patients and experienced patients take into account the risk 26 
benefit ratio and the viral genotype. Current guidelines recommend in 27 
treatment-naïve patients a combination of a ritonavir boosted PI or a NNRTI plus two 28 
NRTIs and in treatment experienced patients a combination of at least two active 29 
ARV drugs from different classes based on viral genotype.[5-7] 30 
Besides entry inhibitors which act on receptors located on cell surface, most ARV 31 
drugs inhibit viral replication inside the cell, therefore intracellular concentration 32 
should be a reliable parameter to consider when relating pharmacokinetics and 33 
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efficacy. Results from several in vitro studies also exist in this area. But, because of 1 
the difficulties of extrapolating the results from in vitro to in vivo studies, in this paper, 2 
we focus only on in vivo studies.  3 
This article summarizes clinical trials where intracellular concentrations were 4 
measured and related to plasma concentrations, virological efficacy or toxicity. Prior 5 
to this presentation and to understand limitations of such studies, the following topics 6 
are presented and discussed: clinical pharmacokinetics of ARVs, intracellular drug 7 
assays and mechanisms influencing intracellular diffusion and accumulation.  8 
 9 
2 Clinical pharmacokinetics of ARVs 10 
Pharmacokinetic parameters of ARVs are summarized in table I. [6, 8-13] 11 
2.1 Entry inhibitors 12 
Entry inhibitors block the virus attachment on receptor of the cell surface. They have 13 
an extracellular mode of action and therefore differ from other available classes of 14 
antiretroviral agents. Two drugs of this class are available, enfuvirtide and maraviroc, 15 
considering their mechanism of action, they are outside the scope of this review. To 16 
have an exhaustive overview of ARVs, their pharmacological properties are briefly 17 
summarized below. 18 
2.1.1 CCR5 inhibitors 19 
CCR5 or CXCR4 chemokine co-receptor antagonists were promising entry inhibitors. 20 
Maraviroc is the first approved drug of this new class. Maraviroc inhibits CCR5 21 
chemokine co-receptor preventing HIV binding to cell membrane. Pharmacokinetic 22 
characteristics have been summarized elsewhere.[14] In brief, maraviroc is a CYP3A 23 
substrate and dosing differs according to combined drugs (150 mg bid with ritonavir 24 
boosted PI, 600 mg bid when combined with drugs with enzyme inducing properties 25 
such as efavirenz and 300 mg bid when combined with nucleoside analogs). 26 
Maraviroc is a P-gp substrate, which limits intracellular concentrations. 27 
Concentrations in cervico-vaginal fluid and vaginal tissue are higher than in plasma.  28 
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2.1.2 Enfuvirtide 1 
Enfuvirtide (T20) is a HIV-1 fusion inhibitor, which prevents fusion of HIV-1 and host 2 
cell membranes. It is a synthetic peptide (4492 Da), which is not bioavailable when 3 
taken orally and is administered subcutaneously twice daily (90 mg bid) which is 4 
obviously a limitation to its long-term use. Pharmacokinetic properties have been 5 
previously reported.[15]  6 
2.2 Nucleoside and nucleotide analog inhibitors of reverse 7 
transcriptase 8 
Zidovudine (ZDV) is the oldest antiretroviral drug; since a number of nucleoside 9 
analogs were developped (zalcitabine, didanosine (ddI), stavudine (d4T) lamivudine 10 
(3TC), emtricitabine (FTC), abacavir (ABC)). Tenofovir (TFV) is a nucleotide analog 11 
obtained after drug administration of tenofovir disoproxil (TDF), its ester prodrug. 12 
Apricitabine is a new NRTI under development. 13 
Although absolute bioavailaility is unknown, bioavailability is supposed to be high for 14 
most nucleoside analogs but ddI, which is degraded at acid pH, and TDF. None of 15 
these drugs are highly protein bound. Elimination of parent compound occurs as 16 
unchanged drug via the kidney or non-CYP drug metabolizing enzymes, therefore 17 
potential for drug-drug interaction is low, although TDF was demonstrated to inhibit 18 
ddI metabolism.[16] Triphosphate (TP) metabolites are the active component of all 19 
nucleoside analogs.They also inhibits to varying degrees human mitochondrial 20 
polymerase γ. Phosphorylation steps occur within the cell and involved kinases, 21 
which are listed in figure 1.[17] Half-life of the active moiety is longer than plasma half-22 
life of the parent compound for all nucleoside analogs. Long half-lifes of TP 23 
metabolites favor once daily dosing for most of nucleoside analogs except ZDV and 24 
d4T, which are administered on a twice-daily basis. TFV is a nucleotide analog for 25 
which the active form is a diphosphate (DP). All NRTIs compete with endogenous 26 
analogs and stop DNA elongation. Nucleosides such as ABC (carbovir (CBV)) and 27 
TFV are much less apt to cause mitochondrial toxicity compared with d4T.[18]  28 
 29 
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2.3 Non nucleoside analog inhibitors of reverse transcriptase 1 
NNRTIs do not require phosphorylation to inhibit reverse transcriptase. Nevirapine 2 
(NVP) and efavirenz (EFV) are the most commonly used. Delavirdine is available in 3 
some countries, and etravirine is a new NNRTI recently approved in the European 4 
Union and in the United States. NVP and EFV have long half-life after single dose 5 
administration. They are metabolized through CYP3A and CYP2B6 and a genetic 6 
polymorphism has been described which explains at least part of interindividual 7 
variability of their total clearance. They both have enzyme inducing and autoinducing 8 
properties, which explains drug-drug interactions and their non linear 9 
pharmacokinetics.[19] 10 
 11 
2.4 Integrase inhibitors 12 
Integrase inhibitors represent a new class. These drugs inhibit the integration of HIV-13 
DNA into the host genome. Raltegravir was approved in early 2008 and elvitegravir is 14 
under development. Raltegravir is rapidly absorbed and plasma concentrations 15 
decline with a terminal half-life of 7 to 12 h which supports a twice daily dosing.[20] 16 
Plasma protein binding is 83%. Biotransformation pathway involved UGT1A1 17 
therefore drug-drug interactions are limited.[21] ATV which inhibits UGT1A1, increases 18 
raltegravir concentrations modestly.[22] Inducers such as EFV, TPV or rifampin 19 
decrease raltegravir concentrations although the clinical consequences are currently 20 
unclear.[21] 21 
 22 
2.5 Protease inhibitors 23 
Protease inhibitors (PI) prevent cleavage of viral precursor protein into the subunits 24 
required to form new virions. Approved PIs include amprenavir (APV), fosamprenavir, 25 
atazanavir (ATV), darunavir (DRV), indinavir (IDV), lopinavir/ritonavir (LPV/r), 26 
nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and tipranavir (TPV). 27 
They all are substrate and inhibitor of CYP3A, which explains part of their poor 28 
pharmacokinetic properties: pre-systemic first pass metabolism, variable plasma 29 
concentrations and short half-life in the 7 to 15 h range. RTV, which is the most 30 
potent CYP3A inhibitor, is combined to all PIs but NFV to improve their 31 
pharmacokinetic properties, increase plasma exposure and /or decrease the 32 
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administered dose.[23, 24] As basic organic chemicals they all are bound to plasma 1 
proteins, α1-glycoprotein acid and albumin. They differ for some pharmacokinetic 2 
parameters, extent of first pass metabolism, extent of protein binding (IDV 60%, LPV 3 
98-99%) and some of them such as APV have inducing properties which make drug-4 
drug interaction prevision very difficult.  5 
 6 
3 Methodological considerations 7 
All intracellular assays described to date do not discriminate between drug localised 8 
in cell membrane or in cytoplasm, either bound to intracellular proteins or truly 9 
unbound which should be the effective antiretroviral moiety. Measurement of total cell 10 
concentrations is somehow of limited value. 11 
3.1 Cell collection 12 
Isolation of PBMCs is the first step before analyzing the intracellular concentrations 13 
of either NRTIs, NNRTIs or/and PIs. PBMCs can be isolated either using 14 
conventional Ficoll gradient centrifugation or using cell preparation tubes (CPTs) 15 
(from Becton Dickinson). The two procedures were compared by Becher et al.[25] on 16 
phosphorylated anabolites of two NRTIs and were shown to give identical results. 17 
However using CPTs was found to be easier, less time-consuming and therefore 18 
quicker which in the case of d4T-TP was most important as the drug was shown 19 
instable in the cell ring of the Ficoll gradient (40% loss within 40 min) and lead the 20 
authors to collect the ring in less than 10 min. However before this isolation step the 21 
stability of the phosphorylated anabolites, that of NNRTIs and PIs in blood should be 22 
considered. 23 
Regarding d4T-TP, its stability has been checked in blood before PBMCs isolation 24 
and the authors recommend to perform the isolation within 6 h after sampling.[26] 25 
Similar results were obtained with 3TC-TP and ZDV-TP.[27] It therefore seems that for 26 
the phosphorylated anabolites the storage of blood samples in CPTs before isolation 27 
could last 6 h, although it has not been thoroughly investigated for CBV-TP and TFV-28 
DP.  29 
Other issues during cell processing are to avoid contamination by red cells which 30 
may phosphorylate some nucleoside analogs[28] and efflux of PIs and NNRTIs out of 31 
cells. In contrast the NRTI-TPs are ion-trapped intracellularly. For NNRTIs and PIs 32 
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intracellular measurements, the collection of PBMCs has not been systematically 1 
studied. The authors mentioned that samples should be immediately taken to 2 
laboratory (within 5 min) and that all the procedures should be performed at 4°C to 3 
inhibit enzymatic activity and to prevent active drug efflux, the time between blood 4 
sampling and the cell isolation and extraction procedure should be less than 1 h.[29, 30] 5 
 6 
3.2 Estimation of cell number 7 
Since the number of cells normalizes intracellular concentration, a critical step in the 8 
processus of intracellular assay is the determination of the number of cells from 9 
which the compounds were quantified. 10 
In most studies when the information is indicated the cells were determined on a 11 
small aliquot with a Coulter Counter, or using a Malassez cell and a microscope. 12 
However this last procedure may suffer from insufficient accuracy and precision, 13 
specifically when multiple sites are involved which explains that a biochemical test 14 
was developed based on the relationship between DNA content and cells count by 15 
Malassez cell.[31] This test could be performed in the analytical laboratories where 16 
there is no Coulter Counter available.  17 
The concentration is therefore expressed as amounts per 106 cells and can be 18 
converted in amount per volume on the approximation that the PBMC volume is 19 
0.4 pL in order to compare intracellular and plasma concentrations.[32] The accuracy 20 
of this volume may be questionable as it varies according to the state of the cells 21 
(quiescent or stimulated) or to the nature of the cells (cell volume of human 22 
lymphoblast : 2.1 pL).[33] This highlights the pitfalls of the conversion. However the 23 
0.4 pL volume is mostly used.[29, 34] This calculation step is critical for the comparison 24 
of the results from different teams, and a standardized procedure should therefore be 25 
chosen. 26 
3.3 Analytical methods for intracellular assays  27 
The approaches regarding the analysis of the intracellular drugs due to the difference 28 
in their concentrations (low about fmol/106 cells for intracellular TP anabolites and 29 
ng/3× 106 cells i.e. about pmol/106 cells for PIs) are quite different. 30 
 31 
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3.3.1 Nucleoside analog inhibitors of reverse transcriptase 1 
The major problem in measuring intracellular TP anabolites is the small amount 2 
present in cells of patients and the presence of the endogenous intracellular 3 
nucleotides able to interfere. Thus, selective and sensitive analytical methodologies 4 
should be developed.  5 
Rodriguez et al.,[35] in 2000 reviewed the latest information regarding the intracellular 6 
in vivo quantification of NRTI-TP. The authors described the first methods used and 7 
pointed out all their drawbacks (lack of sensitivity, cumbersome assays, inability to 8 
differentiate NRTI-TP from the endogenous nucleotides, lack of internal standard). 9 
More recent approaches were based on the same first steps, i.e. separation of ZDV-10 
anabolites using anion-exchange cartridges, cleavage of the phosphate group using 11 
acid phosphatase, addition of an internal standard after enzymatic digestion, 12 
desalting and quantification by HPLC-MS/MS. Moreover the calibration curve was 13 
prepared from ZDV-TP contrary to the previous procedures, which used the parent 14 
compound. The limit of detection was 4.0 fmol/106 cells. The authors applied the 15 
same procedure to the simultaneous determination of ZDV-TP and 3TC-TP.[36] The 16 
limit of quantification was 0.1 pmol and 4.0 pmol for ZDV-TP and 3TC-TP, 17 
respectively. Moore et al.,[37] improved this procedure describing an analytical 18 
method which allows to measure simultaneously intracellular 3TC-TP, d4T-TP and 19 
ZDV-TP with HPLC-MS/MS. The limits of detection were 5, 25, 25 pg on column for 20 
3TC-TP, d4T-TP, ZDV-TP respectively. Similar methods were applied by King et 21 
al.,[38] to measure TFV-DP and by Robbins et al.,[39] to measure simultaneously ZDV-22 
TP, TFV-DP and 3TC-TP in PBMC i.e. isolation by anion exchange, addition of a 23 
stable labeled isotope, dephosphorylation, desaltation and detection by LC MS/MS. 24 
The lower limit of quantification were 10 fmol/106 cells for TFV-DP[38]  and 0.11 25 
pmol/106 cells, 2 fmol/106cells and 3.75 fmol/106 cells for 3TC-TP, ZDV-TP and TFV-26 
DP respectively for a sample size of 106 cells.[39] Most of these indirect methods are 27 
quite labor-intensive, involving multiple steps, which may restrict their use to 28 
specialized laboratories. 29 
New methodologies were described based on direct HPLC-MS/MS determination on 30 
the cellular extracts without dephosphorylation. However these processes need the 31 
use of ion pairing agents to circumvent the poor retention of the nucleotides which 32 
most of them are incompatible with ionisation mass spectrometry. Pruvost et al.[26] 33 
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described the direct determination of d4T-TP as well as that of the endogenous 1 
competitor deoxythymidine triphosphate (dT-TP). Just before cell lysis, an internal 2 
standard was added. The instrument was operated in the electrospray negative ion 3 
mode under MS/MS conditions. The limit of quantification was 9.8 fmol/106 cells i.e. 4 
20 pg injected for d4T-TP. In this article the authors focus on the stability of the d4T-5 
TP at the different steps (in blood,  in the cells ring, in dry  cells at 4°C, after cell lysis 6 
at 4°C, in the injection solvent at room temperatur e). This procedure is very simple to 7 
perform as it does not need any extraction step. However due to the very high pH of 8 
the mobile phase (ion pairing agent: 1,5-Dimethylhexylamine) the column was 9 
changed every two weeks.[40]   10 
With slight modifications regarding the internal standard and the chromatographic 11 
column, the same authors were able to measure simultaneously d4T-TP, 3TC-TP 12 
and ddA-TP (active anabolite of ddI) with their corresponding natural nucleotides in 13 
the same run.[25] However regarding ZDV-TP, a massive and tailing peak was 14 
observed near the retention time of ZDV-TP, which precludes the analysis of ZDV-TP 15 
simultaneously with d4T-TP, 3TC-TP and ddA-TP. To overcome this problem Becher 16 
et al.,[41] developed a specific extraction of ZDV-TP using immunoaffinity and 17 
detection of ZDV-TP using LC-MS/MS. More recently the same group improved the 18 
specificity and obtained a slightly better sensitivity for 3TC-TP, CBV-TP and TFV-TP 19 
using a positive electrospray ionization mode. [42] 20 
Although the direct methods should be faster and more precise King et al.,[43] were 21 
unsuccessful in reproducing these methodologies. In particular they pointed out the 22 
difficulty in analyzing ZDV-TP due to the large amount of ATP and to the interference 23 
with dGTP, these latter compounds having the same precursor ion and the same 24 
product ion. This was evidenced by Compain et al.,[44] who developed an improved 25 
method to determine ZDV-TP. The authors chose a minor but specific fragment ion 26 
and had to spike their sample with a constant amount of ZDV-TP to allow the signal 27 
to emerge from background in order to increase the sensitivity.  28 
HPLC-MS/MS is susceptible to matrix effects, i.e. co-eluting matrix components that 29 
affect the ionization of the target analyte, resulting in ion suppression, or, in some 30 
cases ion enhancement.[45] For intracellular assay the main parameter to study is the 31 
influence of the number of cells in the sample, as it cannot be fixed. The matrix effect 32 
plus recovery was tested by Becher et al.,[46] on d4T-TP and ddA-TP and the 33 
influence of the cell number was evidenced. The use of an appropriate internal 34 
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standard controlled the influence of the matrix effect between 7 and 14× 106 cells for 1 
the simultaneous assay of d4T-TP and ddA-TP. However the use of stable isotope 2 
analog as internal standard would be the best choice to control the influence of the 3 
matrix effect.  4 
Monitoring the very low intracellular concentrations of these active anabolites 5 
remains an analytical challenge. All the methods described have their drawbacks.  6 
However they are all based on sophisticated methods, which can be hardly 7 
reproduced, so each laboratory favors the analytical procedure in which it is familiar. 8 
Whatever the choice regarding the procedure, indirect or direct, it appears that the 9 
quantification of the compounds using HPLC coupled to MS/MS is very specific and 10 
may circumvent all the drawbacks due to the multiple natural nucleotides that are 11 
found in the complex mixture of the intracellular medium that can interfere with the 12 
determination of intracellular phosphorylated anabolites of NRTIs. 13 
 14 
3.3.2 Non nucleoside analogs and protease inhibitors 15 
The measurement of intracellular concentrations of NNRTIs and PIs could be 16 
obtained using HPLC-UV detection as was it published for EFV[34] and for 10 of them  17 
(NVP, DLV, APV, IDV, metabolite of NFV (M8), RTV, LPV, EFV, SQV, NFV)[47]. 18 
However most reported data were obtained using LC-MS/MS methods either for one 19 
drug[48] or for the simultaneous measurement of several of them. The method 20 
involved automated solid-phase extraction[48], liquid-liquid extraction ((APV, LPV, 21 
SQV, EFV)[49], NVP[30], (LPV, RTV)[50]) or single-step extraction  ((NVP, DLV, APV, 22 
IDV, M8, RNV, LPV, EFV, SQV, NFV)[47], (IDV, APV, SQV, RTV, NFV, LPV, ATV, 23 
EFV)[29]). Few quantitative immunoassays were published for the intracellular 24 
determination of LPV and ATV.[51, 52] These methods imply the preparation of a 25 
polyclonal antibody obtained with a synthetic antiretroviral drug derivative coupled to 26 
hemocyanin or serum albumin as the immunogen and the chemical synthesis of an 27 
enzyme tracer. Obviously these methods are not available in most laboratories, 28 
which preclude their use as useful tools to study the intracellular concentrations of 29 
NNRTIs and PIs.  30 
 31 
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4 Mechanisms influencing intracellular accumulation 1 
4.1 General principles  2 
As already stated, most ARVs acting on cell receptors need to enter the cell to bind 3 
to antiretroviral targets, reverse transcriptase, integrase or protease. In general, 4 
disposition from systemic circulation and capillary lumen to the extravascular 5 
compartment occurs by diffusion or involves active transporters 6 
Simple diffusion is generally the most common mechanisms for transmembranal 7 
movement of xenobiotics in the body. The rate of diffusion is defined by Fick’s law 8 
and accordingly the small, lipophilic, unionised and unbound molecules readily 9 
diffuse across the membrane. Difference in the pH gradient between plasma and 10 
lymphocytes could explain ion trapping. As reported by Ford et al.[53], the pH gradient 11 
between plasma and lymphocytes is subject to change depending on the membrane 12 
potential. Binding of drugs to plasma proteins may slow diffusion rate as only free 13 
unbound drug will cross biological membranes. However basic drugs which have 14 
higher affinity for cells or tissues proteins than for plasma proteins may leave very 15 
rapidly the blood stream and protein binding is not a limiting factor; for such drugs, 16 
volume of distribution is high, the amount of drug in plasma small compared to the 17 
amount in tissues and cells and small changes in plasma protein binding will not 18 
affect the amount in extra vascular compartments.[54] Membrane transporters (efflux, 19 
influx) are now recognized to play an important role in drug absorption and 20 
disposition and to explain, at least in part, the broad interindividual variability in 21 
intracellular concentrations of drugs. Figure 2 summarizes the different carrier 22 
proteins determining intracellular concentrations within a typical immune cell.[53, 55-57] 23 
Efflux transporters which operate at the expense of adenosine triphosphate (ATP) 24 
hydrolysis are members of ATP-binding cassette (ABC)-type transport proteins and 25 
are now well studied. P-gp was first described for its ability to reduce intracellular 26 
concentrations of anticancer compounds. Other multidrug resistance proteins (MDR) 27 
have been isolated since. They are expressed in the apical membrane of many 28 
barrier tissues such as the intestine, liver, kidney, blood-brain-barrier, placenta, testis 29 
and in immune cells. Relevance for pharmacotherapy of expression of ABC drug 30 
transporters in peripheral blood cell have been reviewed recently.[57] The Breast 31 
Cancer Resistance Protein (BCRP) was found to play a major role in nucleoside 32 
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efflux.[58, 59] Although influx transporters are not as well studied, several proteins have 1 
been identified for nucleosides transport (Solute Carrier, SLC); they differ by their 2 
mechanism of action. Some are powered by electrochemical gradient (Concentrative 3 
Nucleoside Transporter hCNT), others are Equilibrative Nucleoside Transporter 4 
(ENT), Organic Cation Transporters (OCT) or Organic Anion transporters (OAT), 5 
although this later was not found to be expressed in immune cells.[53, 60] 6 
Several factors may influence transporters expression within cell membrane, cell 7 
subsets and functionality, activation state of cells and polymorphism of coding genes. 8 
Polymorphism in the coding region of the transporter genes has been evidenced 9 
which lead to produce functional changes in the encoded transporter protein and 10 
result in variation in drug disposition and response, however the studies are 11 
scanty.[55] Several factors which could affect intracellular concentrations of ARVs 12 
have to be taken into consideration: drug affinity and expression of the transporters 13 
according to different cells or tissues, and many of these transporters are known to 14 
be modulated by co-administrated ARVs.  15 
 16 
4.2 Nucleoside and nucleotide analog inhibitors of reverse 17 
transcriptase  18 
Data on nucleoside analogs (purine or pyrimidine base coupled to a sugar) cellular 19 
penetration are scarce. As they are more hydrophilic compounds, it was suggested 20 
that they could be substrates of the endogenous nucleoside transporters.[61, 62] 21 
Although studies demonstrated that cerebral penetration occurs mainly by passive 22 
diffusion and that the low concentration of nucleoside in brain is the consequence of 23 
active efflux transporters[63], expression of uptake transporters in lymphocytes could 24 
favor high intracellular concentrations. It was evidenced that ZDV-TP and 3TC-TP 25 
concentrations were effluxed by MRP4 and BCRP. TFV as a nucleotide has an 26 
ionized phosphate group, which confers acidic properties. It was demonstrated that 27 
TFV uptake in the kidney proximal tubule basolateral membrane is mediated via 28 
OAT1 and cellular efflux into the urine via MRP2 and MRP4.[64] TP concentrations 29 
differ according to cell type most likely as a consequence of influx and efflux 30 
transporters expression. In healthy volunteers, 3TC-TP concentrations were close in 31 
PBMCs and purified CD4 cells, whereas ZDV-TP concentrations were lower in CD4 32 
cells than in PBMCs.[65] Concentrations of TFV-DP were compared in PBMC, lymph 33 
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node tissue and digestive lymphatic tissue and were higher in PBMCs than in other 1 
tissues.[66] These data strongly suggest that transporters localisation may differ 2 
according to cell functionality. Kinase activity could also influence the intracellular 3 
concentration of TP. In vitro experiments suggested this activity varies greatly and is 4 
lower in resting cells than in activated PBMC.[67, 68] This could have important 5 
consequences as kinases activity will govern the intracellular level of both 6 
endogenous triphosphates and NRTI-TP which compete at the level of HIV-reverse 7 
transcriptase. All NRTIs have been demonstrated to be more effective in monocyte 8 
derived macrophages which are important HIV1 reservoirs than in CD4+T 9 
lymphocytes.[69] These could also well explain the differences in NRTI-TP intracellular 10 
concentrations according to different cell types and different activation state.[28] 11 
 12 
4.3 Non nucleoside analog inhibitors of reverse transcriptase 13 
NNRTIs are weakly acidic and predominantly bind to albumin. Neither EFV nor NVP 14 
were thought to be substrate of P-gp.[70] In a limited number of patients, Almond et 15 
al.,[34] demonstrated a relationship between intracellular concentration of EFV and 16 
% bound EFV in plasma. Such data are in contrast with those obtained with NVP by 17 
the same team.[30] They demonstrated that intracellular concentrations of NVP are far 18 
below those measured in plasma. Intracellular concentration was negatively related 19 
to P-gp expression, but not related to plasma % unbound NVP.[30] To explain these 20 
data, the authors suggest that NVP could induce P-gp or co-regulated efflux 21 
transporter. Clearly, to understand all mechanisms, which are involved in intracellular 22 
concentrations of NNRTIs, further studies are needed. 23 
 24 
4.4 Protease inhibitors 25 
The intracellular pharmacology of PIs has been carefully reviewed by Ford et al.[53]. 26 
The PI physio-chemical properties are in favour of passive transfer: 27 
 - The transfer is in agreement with lipophilicity measured by the n-octanol to water 28 
partition coefficient. Accumulation of PIs in lymphocytes reflects the rank order of 29 
lipophilicity: the less lipophilic PI being IDV and the most lipophilic NFV. 30 
- PIs are weak bases and are mostly unionized in a basic environment; intracellular 31 
sequestration is dependant upon pH gradient between plasma and cells. 32 
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- Protein binding of PIs to α1-acid glycoprotein ranged from 60% for IDV to 97-99% 1 
for RTV, LPV, SQV and NFV. However protein binding per se is not a limiting factor 2 
to intracellular diffusion as IDV, which is 60% bound, has lower intracellular 3 
concentrations than other PIs more highly bound. Within the cell PIs are bound to 4 
cell proteins and HIV proteases and therefore their relative affinity for each protein 5 
may influence their dynamic equilibrium.[53] 6 
However active transport may play a role in the intracellular accumulation. It is now 7 
well established that PIs are substrates of P-gp and others efflux transporters such 8 
as MRP1[71] or MRP2[72]. P-gp is expressed in the gastro-intestinal tract and the liver 9 
and act with CYP3A to reduce their bioavailability. RTV combined to most PIs as a 10 
pharmacologic enhancer inhibits both CYP3A and P-gp and markedly increases the 11 
bioavailability of PIs. Such transporters are expressed on lymphocytes and may 12 
reduce cellular accumulation. Meaden et al.,[73] found a relationship between 13 
combined expression of P-gp and MRP1 on PBMCs of HIV-infected patients and 14 
intracellular accumulation of SQV and RTV. In summary, there are evidences that 15 
intracellular concentration of PIs depends on P-gp and/or other efflux transporters 16 
activity, which is modulated by genetic polymorphism and coadministration of drugs 17 
with inhibiting or inducing properties. How these transporters will control intracellular 18 
concentrations of PIs need further studies. 19 
 20 
4.5 Importance of genetic polymorphism 21 
At evidence, the role of transporters and their genetic polymorphism in drug 22 
disposition should be considered[74] and reviews have summarized findings from 23 
recent pharmacogenetics studies.[55, 75]  24 
La Porte et al.,[76] studied the relationship between ABCB1 (MDR1) genetic 25 
polymorphism, P-gp expression and SQV or SQV/r pharmacokinetics in 150 healthy 26 
volunteers. No relationship was found between the C3435T, G2677T/A or C1236T 27 
polymorphisms of the ABCB1 gene and the pharmacokinetics of SQV or the 28 
expression and activity of P-gp in PBMCs. Seventy one HIV-infected children treated 29 
with a NFV backbone antiretroviral drug regimen were evaluated for MDR1 30 
polymorphism (MDR1 C3435T), NFV plasma concentrations, CD4 cell count and 31 
HIV-RNA.[77] Children with the C/T genotypes had higher 8h post dose NFV 32 
concentrations and more rapid response to HAART. Unfortunately, intracellular 33 
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concentrations of PIs were not measured in these studies. In contrast, in 12 HIV-1 
infected patients, Ford et al.,[78] could not evidenced higher intracellular 2 
concentrations of NFV or its M8 metabolite and lymphocyte cell surface expression of 3 
P-gp. In a cohort of 47 patients treated with PI boosted or not by RTV, Chaillou et 4 
al.,[79] demonstrated that intracellular concentration of RTV was related to 5 
undetectable plasma HIV-RNA, which was not related to MDR1 gene expression. 6 
Interestingly the importance of MRP4 carrier was evidenced by Anderson et al.,[72], 7 
as they demonstrated that patients carrying MRP4 T4131G had elevated 3TC-TP 8 
concentrations and patients with MRP4 G3724A had a trend for elevated ZDV-TP. 9 
They also found that IDV clearance was faster in patients expressing CYP3A5 and in 10 
patients carrying the MRP2-24C/T variant[72]; whether this latter may contribute to 11 
lower intracellular concentrations remains to be established. 12 
Recently, Kiser et al.,[80] demonstrated that intracellular concentrations of TFV-DP 13 
were higher, first with decrease in kidney glomerular filtration rate and consequently 14 
total and renal clearance of TFV (p=0.04) and second in presence of the ABCC4 15 
3463 A>G variant (p=0.04 after adjustment for race, treatment group and glomerular 16 
filtration rate). The authors pointed out the limitation of this small sample size study 17 
for genetic association and thus results should be confirmed in larger study. Whether 18 
those exploratory data could be extrapolated to intracellular concentration of TFV-DP 19 
within renal proximal tubule cells is presently unknown. 20 
At evidence, the control of intracellular concentrations of ARVs is complex and 21 
dependant on many factors and more work is needed in this area taking into account 22 
the differences in cell biology. 23 
 24 
5 Clinical studies with intracellular concentrations 25 
5.1 Relationship between intracellular and plasma 26 
pharmacokinetics 27 
Clinical studies performed in HIV-infected patients reporting intracellular 28 
concentrations are summarized in table II.[9-13, 30, 34, 72, 78, 79, 81-101] They are displayed 29 
by antiretroviral class, then within an antiretroviral class they are listed by molecule 30 
with respect to the date of Health Authority approval. For each molecule, the more 31 
recent studies are presented first. All those studies were published after 2000, except 32 
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for ZDV for which intracellular concentrations have been studied since 1994. Most 1 
studies reported both plasma and intracellular concentrations but only few of them 2 
studied the relationship between them.  3 
It can be seem from table II that plasma pharmacokinetic parameters are rather 4 
similar across studies but some differences are observed for intracellular parameters. 5 
For NRTIs, most studies did not established significant relationship between plasma 6 
and TP concentrations. In contrast for NNRTIs and PIs results are more conflicting, 7 
some studies evidencing correlation, while others could not. These results support 8 
the use of plasma concentration of NNRTIs or PIs but not NRTIs to monitor antiviral 9 
efficacy. 10 
Such results are not surprising knowing first that PBMCs collection, preparation and 11 
quantification are not an easy task (see section 3) and second that many factors 12 
influence intracellular drug penetration and among them genetic polymorphism of 13 
influx and efflux carriers (see section 4). Moreover, these intracellular studies have 14 
been carried out in relatively few patients and larger studies would be needed to 15 
address consistently the relationship between plasma and intracellular 16 
concentrations of ARVs.  17 
It is also important to note that there are potential methodological problems when 18 
studying relationship between concentrations observed at single time points, as it is 19 
done in a number of studies. Indeed, plasma and intracellular half-life are very 20 
different. It is more adequate to assess the relationship through pharmacokinetic 21 
parameters such as AUC. Surprisingly, most studies reported concentrations at some 22 
time points or PK parameters obtained by non-compartmental analysis. Population 23 
approaches were never used to analyse intracellular concentrations and their link 24 
with plasma concentrations, although this approach seems more appropriate as it 25 
allows to analyze sparse measurements. 26 
5.2 Drug-drug interactions at the intracellular level 27 
On a theoretical point of view, changes in the intracellular concentration of 28 
antiretroviral drugs can be secondary to modifications of (i) plasma concentration of 29 
the drug and/or the prodrug, (ii) activity of the enzymes responsible for drug 30 
anabolism/metabolism at the cellular level, (iii) activity of membrane transporters 31 
involved in cellular uptake or efflux. Since the intracellular amount of the active drug 32 
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is responsible for treatment efficacy, interactions leading to changes in intracellular 1 
concentrations are a relevant issue regarding the virologic outcome. 2 
The clinical impact of these interactions was first evidenced by the poor efficacy of 3 
therapies combining ZDV with d4T.[102] Though the likely mechanism of this result, 4 
competitive inhibition of d4T phosphorylation by ZDV, was assessed only by in vitro 5 
experiments, this phenomenon highlighted the necessity to investigate the possible 6 
alteration in the intracellular concentrations of ARVs due to drug association.[103, 104] 7 
Potential interactions involving NRTIs at the intracellular level were therefore 8 
investigated in several studies. Hawkins et al.,[82] evaluated whether the high rate of 9 
virological failure observed in patients receiving a triple NRTIs combination including 10 
TDF could be explained by modifications in the intracellular anabolism of these 11 
compounds. 12 
So, intracellular levels of TFV-DP, CBV-TP and 3TC-TP were measured in 15 HIV-13 
infected patients receiving a triple NRTI combination (TDF-ABC-3TC or TDF-ABC- 14 
d4T), before and after replacement of TDF or ABC by a NNRTI or a PI. No 15 
modification in the intracellular concentrations of the active anabolites of the 16 
remaining NRTIs was observed, which suggested the lack of significant interaction 17 
between the investigated drugs. Another recent study confirmed these results on 27 18 
patients.[105] Taken together, these results suggest the clinical failure that was 19 
observed with the triple NRTI (ABC/TDF/3TC) regimen was not due to drug 20 
interactions but was more likely the consequence of lack of intrinsic power.[106] This 21 
latter study also evidenced a significant 50% increase in the intracellular 22 
concentration of TFV-DP when TFV was combined to LPV/r. However, this result 23 
could simply be the intracellular reflection of the systemic interaction between these 24 
two drugs.[107] This study found no significant difference in the intracellular 25 
concentrations of CBV-TP and 3TC-TP with respect to LPV/r use, despite a 46% 26 
decrease in ABC plasma concentration in the LPV/r group. Last, nevirapine was also 27 
found not to significantly modify the intracellular concentrations of TFV-TP, CBV-TP, 28 
and 3TC-TP. 29 
Hoggard et al.,[108] investigated whether prior exposure to ZDV could subsequently 30 
inhibit d4T phosphorylation. The rationale for this study came from the observation 31 
that naïve patients receiving a d4T -3TC combination experienced a further one log10 32 
decrease in viral DNA compared to patients previously treated by ZDV.[109] A 33 
subsequent inhibition of d4T phosphorylation due to a down regulation of thymidine 34 
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kinase induced by ZDV was one of the hypotheses raised to explain this result. 1 
However, the cellular concentration of d4T-TP measured in 7 ZDV-experienced 2 
patients was not different to the concentration measured in 20 ZDV-naïve subjects. 3 
Furthermore, the ability of PBMCs to phosphorylate d4T was not different between 4 
ZDV-experienced and ZDV-naïve subjects.[108] Similarly, no influence of prior 5 
exposure to ZDV on ZDV phosphorylation was observed during a 12 months period 6 
on 23 HIV-infected patients. [83] It is therefore likely that the decrease in efficacy 7 
observed in ZDV-experienced patients was due to the acquisition of resistance 8 
mutations rather to a modification in intracellular metabolism. 9 
By measuring the TP moieties of ZDV and 3TC in the PBMCs of 8 patients, Fletcher 10 
et al.,[84] found a strong correlation between the intracellular concentrations of ZDV-11 
TP and 3TC-TP. If this result suggested the existence of interplay among the cellular 12 
anabolism and/or metabolism of these drugs, its precise mechanism and possible 13 
consequences have still not been elucidated. 14 
TDF is known to increase the plasma concentration of ddI, the most likely 15 
mechanism for this interaction being the inhibition by TVF of the enzyme responsible 16 
for the hydrolysis of guanosine and adenosine analogues, the purine nucleoside 17 
phosphorylase.[16] This interaction is clinically relevant since it is responsible for 18 
adverse effects[110-113] or treatment failure[114] which may be secondary to didanosine 19 
overexposure. Because of this, this association is currently not recommended for the 20 
initiation of HAART, but is nevertheless not countraindicated for ulterior lines of 21 
treatment.[6] Pruvost et al.,[85] investigated the possible consequences of this 22 
systemic interaction on the intracellular concentrations of the active moieties. 23 
Intracellular concentrations of ddA-TP and TFV-DP were compared between 14 24 
patients receiving the ddI/TDF (250 mg/300 mg) combination and 16 patients 25 
receiving ddI (400 mg) without TDF or 14 patients receiving TDF (300 mg) without 26 
ddI. The measured concentrations were found to be comparable between the groups 27 
which validated the strategy consisting in decreasing ddI dose from 400 to 250 mg 28 
when it is combined with TDF.[115] 29 
Apricitabine, a novel deoxycitidine analog currently under investigation, shares its 30 
initial phosphorylation pathway by deoxycytidine kinase with 3TC and FTC. The 31 
potential interaction between apricitabine (600 mg bid) and 3TC (300 mg qd) was 32 
evaluated in a crossover study performed on 21 healthy volunteers who received 33 
sequentially each drug separately and the combination of both. No significant 34 
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modification in the plasma pharmacokinetics of 3TC, or in the cellular 1 
pharmacokinetics of its active TP moiety was observed during the combination 2 
compared to the monotherapy period. However, if co-administration with 3TC had no 3 
influence on apricitabine plasma pharmacokinetics, cellular concentration of 4 
apricitabine TP dropped by 85% during the same period.[116] These findings strongly 5 
suggested that apricitabine should not be co-administered with deoxycitidine 6 
analogues. 7 
Hydroxyurea is an antiproliferative drug that was shown to provide a further 0.7 log10 8 
reduction in plasma HIV RNA when combined with ddI compared to patients 9 
receiving ddI alone.[117] By measuring intracellular deoxyadenosine triphosphate (dA-10 
TP) in 69 HIV-infected sujects, it was evidenced that patients receiving the 11 
hydroxyurea-ddI combination achieved significantly lower dA-TP concentrations than 12 
patients under ddI or hydroxyurea monotherapy, whereas no modification in the 13 
plasma pharmacokinetics of the two drugs was observed.[118] If the precise 14 
mechanism of this interaction is still unknown, the likely explanation for the 15 
enhancement of ddI’s efficacy is the decrease in the intracellular dA-TP/ddA-TP ratio, 16 
which would facilitate the incorporation ddA-TP in the replicating viral DNA. 17 
Similarly to hydroxyurea, mycophenolic acid, an immunosuppressive agent, is known 18 
to decrease the intracellular concentration of an endogenous nucleotide, the 19 
deoxyguanosine triphosphate (dG-TP), which could enhance the antiviral activity of 20 
abacavir by decreasing the dG-TP/CBV-TP ratio.[119] Since this ratio could not be 21 
measured to date in patients receiving the mycophenolate mofetil–ABC combination, 22 
this hypothesis still needs to be confirmed. Nevertheless, the lack of influence of 23 
mycophenolic acid on 3TC phosphorylation was sugested by the similar intracellular 24 
concentration of 3TC-TP observed in patients receiving 3TC with or without 25 
mycophenolate mofetil.[86] 26 
Ribavirin is a nucleoside analogue used for the treatment of hepatitis C virus (HCV) 27 
infection. Although its mechanism of action is still not fully understood, it involves at 28 
least in part an intracellular transformation into a TP moiety.[120] Thus, because 29 
ribavirin is used in HIV/HCV coinfected patients, its potential interactions with NRTIs 30 
were investigated in several studies. 31 
Rodriguez-Torres et al.,[121] evaluated the combination of ribavirin with 3TC, d4T, or 32 
ZDV in HIV/HCV coinfected patients. Plasma concentrations of ZDV, d4T, 3TC and 33 
intracellular concentrations of ZDV-TP, d4T-TP, 3TC-TP were measured in 31 34 
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patients receiving concomitant ribavirin and compared to the concentrations obtained 1 
in 25 patients receiving a placebo instead of ribavirin. No significant difference in 2 
plasma and cellular concentrations of the measured compounds was observed, 3 
suggesting ribavirin does not modify the plasma pharmacokinetics and the 4 
intracellular phosphorylation of ZDV, d4T, 3TC. The lack of interaction between 5 
ribavirine and ZDV was confirmed in another study performed on 14 HIV-infected 6 
subjects.[122] 7 
It is noteworthy these results are discrepant with in vitro data which evidenced an 8 
inhibition of the phosphorylation of ZDV[123, 124] and d4T[104] by ribavirin. However it is 9 
still unexplained whether these discrepancies are due to a poor ability of in vitro 10 
models to predict in vivo phenomenon or to some methodological drawbacks in the 11 
ex-vivo quantification of intracellular TP moieties. 12 
Oppositely, ribavirin was found to potentiate in vitro the phosphorylation of ddI via the 13 
inhibition of inosine 5-monophosphate dehydrogenase.[125] However, despite its 14 
potential virologic interest, this interaction is also characterized by a high risk of 15 
mitochondrial toxicity[126, 127], so the ribavirin-ddI association is not recommended. 16 
Concerning PIs, the influence of ATV on the plasma and intracellular 17 
pharmacokinetics of SQV and RTV was investigated in 9 HIV-infected patients who 18 
received the SQR/RTV (1600/100 mg qd) combination with and without ATV (200 mg 19 
qd). ATV was found to significantly increase both plasma and intracellular 20 
concentrations of SQV by a similar factor of approximately 4, but had no effect on 21 
RTV concentrations.[128] Interestingly, the cellular half-life of SQV was unaffected by 22 
ATV, which suggested the increase in the intracellular concentration was secondary 23 
to the increase in plasma concentration rather to the inhibition of a cellular 24 
transporter. 25 
The possible modification of plasma and cellular concentrations of SQV by quercetin, 26 
a bioflavonoid displaying inhibitory properties on CYP3A4 and P-gp, was investigated 27 
on 10 healthy adults who received SQV alone (1200 mg bid) for 11 days followed by 28 
the association SQV/quercetin (1200 mg bid/500 mg bid) during the next three 29 
days.[129] If no change was observed for SQV plasma concentration, its intracellular 30 
concentration surprisingly decreased by almost 50% when combined with quercetin. 31 
However, the important intra and intersubject variability of the intracellular 32 
concentrations prevented to draw conclusions from this result. 33 
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The accumulation ratio, equal to the cellular concentration divided by the plasma 1 
concentration, of some PIs was found to be modified by low doses of RTV in HIV-2 
infected subjects.[79] APV and IDV accumulation ratios in presence of 100 mg or 400 3 
mg of RTV were indeed increased three-fold and five-fold respectively. However, 4 
conflicting results were obtained in another study which found that RTV did not 5 
increase the accumulation ratio of SQV and IDV.[130] 6 
Despite these discrepencies, assessing the consequences of drug interactions at the 7 
cellular level is of great concern in order to validate new combinations. Some recent 8 
surprising results, like the possible decrease in the efficacy of HCV therapy due to 9 
ABC[131], evidenced the need for a better understanding of drug interactions. 10 
 11 
5.3 Relationship between intracellular concentrations and efficacy 12 
Only eight studies were published reporting an analysis of the relationships between 13 
intracellular concentrations and virological or immunological efficacy of antiretroviral 14 
drugs in HIV patients. Five studied intracellular NRTIs and three PIs. These articles 15 
are summarized in table III by molecule from the most recent to the oldest one.[8, 79, 84, 16 
87-89, 122, 132]
 Of note, five were prospective study and interestingly found a significant 17 
relationship between higher intracellular concentrations and virological response.[8, 84, 18 
87, 88, 132]
 The correlation with plasma concentration was not always studied but was 19 
mainly not or less significant. The three studies with non significant results were 20 
cross-sectional studies not designed for that purpose.[88, 89, 122]  We start as in table II 21 
by the results on NRTIs and then on PIs, there is no such study for NNRTIs. With 22 
nucleoside analogues, it is important to notice that the relevant determinant of 23 
pharmacodynamic response is the ratio between drug triphosphate and endogenous 24 
nucleoside triphosphates rather than the absolute intracellular concentration.[133] 25 
The study by Moore et al.,[87] was a substudy of the ACTG 862, a prospective trial 26 
where naïve patients were starting a dual NRTI therapy. A significant correlation 27 
between change in viral load between week 0 and week 28 and intracellular 28 
concentrations was found for 3TC-TP (R2= 0.62) in the 39 patients receiving either 29 
3TC-ZDV or 3TC-d4T, and for ZDV-TP (R2= 0.28) in the 10 patients receiving 3TC-30 
ZDV. No significant correlation was found for d4T-TP in the 15 patients receiving 31 
3TC-d4T and no significant relationship was found for any drug when studying 32 
change in CD4 cells.  The authors did not study the relationships between efficacy 33 
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and plasma concentration but showed a very large interpatient variability in the 1 
intracellular to plasma concentration ratio. The authors also showed that there was 2 
an important increase of intracellular concentration between first dose and week 28 3 
only for 3TC-TP. 4 
The study of Aweeka et al.,[122] was performed in HCV or HBV co-infected HIV 5 
patients and its primary objective was to study the influence of ribavirin on ZDV 6 
plasma and intracellular concentrations by measuring the AUC in patients before and 7 
after introduction of ribavirin. Different regimens were allowed and all patients had to 8 
receive ZDV for at least 4 weeks. In the cross-sectional analysis performed in 13 9 
patients before receiving ribavirin, no significant relationships was found between 10 
AUC of ZDV-TP and the CD4 cell count measured the same day.  11 
The studies by Anderson et al.,[8] and Fletcher et al.,[84] are substudies of the well 12 
known concentration-controlled randomised trial by Fletcher et al.,[134]. In this trial 13 
patients received a tritherapy with ZDV, 3TC and IDV either with a fixed dose or with 14 
a dose adapted to get trough concentrations in a define range. Intracellular 15 
concentrations of ZDV-TP and 3TC-TP were measured 2 h after dose administration 16 
at the three pharmacokinetics visits scheduled at weeks 2, 26 and 52 and at variable 17 
time post dose at the nine bimontly visits. For each patient the median intracellular 18 
concentration from all measurements was considered for the analysis of the link with 19 
efficacy. Unfortunately the authors did not analyse intrapatient variability of these 20 
concentrations.   21 
In their first study[84], only 8 patients were studied and the efficacy criteria were the 22 
change between baseline and week 24 HIV RNA or the percent change between 23 
baseline and week 24 CD4 cell count. For ZDV-TP a significant correlation with 24 
intracellular concentrations was found both for changes in HIV RNA (R2=0.54) and 25 
CD4 cells (R2=0.84). For 3TC-TP a significant correlation with intracellular 26 
concentrations was found for changes in HIV RNA (R2=0.79) but not for CD4 cells 27 
(P=0.07, R2=0.44). There was no significant correlation between efficacy and steady-28 
state plasma concentration of these drugs. 29 
In the article by Anderson et al.,[8], 33 patients were studied; the analysis was very 30 
thorough with various efficacy endpoints and with several multivariate analyses. After 31 
a first simple correlation study, the authors defined thresholds for intracellular 32 
concentrations as the first quartiles, which are of 30 fmol/106 cells for ZDV-TP and of 33 
7017 fmol/106 cells for 3TC-TP. They then studied the impact on several efficacy 34 
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endpoints of having a median intracellular concentration below or above those 1 
thresholds. The first efficacy endpoint was the time to plasma HIV RNA less than 50 2 
cp/mL, using a survival analysis. For ZDV-TP, the median time to less than 50 cp/mL 3 
is significantly reduced in patients with ZDV-TP above the threshold than in patients 4 
below as shown.[8] A significant relationship was also found for 3TC-TP but only ZDV-5 
TP remained in the multivariate analysis. The second efficacy endpoints were the 6 
virological status (< 50 cp/mL) at week 24 and at week 52 after starting ARVs drug 7 
regimen. For ZDV-TP, 92% of patients with concentrations above threshold were 8 
undetectable at week 24, this proportion was significantly lower (44%, P=0.009) for 9 
patients below the threshold; but this relationship was not significant at week 52. For 10 
3TC-TP, 96% of patients with concentrations above threshold were undetectable at 11 
week 24, proportion that was significantly higher than for patients below the threshold 12 
(37.5 %, P=0.002); similarly at week 52, 91.7% of patients above threshold were 13 
undetectable which is significantly higher than for patients below the threshold  (25%, 14 
P=0.0008). Another efficacy endpoint was the time to rebound (two HIV RNA greater 15 
than 50 cp/mL), this time was shorter for patients with ZDV-TP and 3TC-TP lower 16 
threshold; in the multivariate analysis only 3TC-TP remains significant (P=0.009). It is 17 
interesting to note that ZDV-TP was mostly associated with the initial viral load 18 
decrease whereas 3TC-TP with sustained response. No significant relationship was 19 
found between CD4 cell count and intracellular concentrations. However, the authors 20 
did not study the change in CD4 cell count but performed cross-sectional analyses 21 
looking for correlation at week 24 and week 52 between CD4 cell counts and 22 
corresponding intracellular concentrations. Link between plasma concentrations of 23 
ZDV and 3TC and efficacy was not studied and no significant relationships were 24 
found with IDV concentrations. The authors also found that intracellular 25 
concentrations were significantly higher in female than in male: 2.3 folds for ZDV-TP 26 
(P<0.0001) and 1.6 fold for 3TC-TP (P<0.0001), whereas no influence of gender was 27 
found on plasma concentrations. These results suggest NRTI phosphorylation 28 
differences between genders. 29 
The first ever published article that analyzed the link between intracellular 30 
concentration and efficacy was the pharmacokinetic trial reported by Stretcher et 31 
al.,[132] where ZDV was given five times a day as a single therapy (500 mg/day) in 21 32 
patients followed during 24 weeks. AUC of total ZDV-phosphates (ZDV-P) was 33 
evaluated at week 4 and week 24 from five samples. Efficacy was analysed mainly 34 
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through CD4 cell count, %CD4 cells and CD4/CD8 ratio. Unfortunately, in the 1 
analysis of the correlation of ZDV-P AUC and immunological efficacy, the authors 2 
pooled the observations made at week 4 and week 24, not taking into account the 3 
correlation induced by the repetition within patients. Here, only results on the 4 
analyses performed separately at week 4 and week 24 are reported. At week 4, the 5 
authors found a significant correlation of ZDV-P AUC both with %CD4 cells change 6 
from baseline (R2=0.06, P=0.029) and with CD4/CD8 change from baseline (R2=0.06, 7 
P=0.028) but not with the value measured at week 4. These correlations were no 8 
longer significant at week 24. No significant correlation was found with plasma AUC.  9 
With respect to studies with PIs, the main objective of the prospective trial reported 10 
by Lamotte et al.,[89] was to investigate the concept of a once daily administration of 11 
the new galenic formulation soft gel capsule of SQV in association with RTV in PI-12 
experienced HIV patients. The evaluation of the link between SQV intracellular 13 
concentrations and virological efficacy in 13 patients was explored as one of the 14 
secondary objectives. No significant correlation was obtained between trough SQV 15 
intracellular concentration at weeks 2, 4 or 12 and variation of plasma HIV RNA 16 
between week 0 and week 12. No significant correlation was found also for plasma 17 
SQV concentrations. 18 
The main objective of the prospective study reported by Breilh et al.,[88] was the 19 
impact on virological success, defined as HIV less than 50 cp/mL, of intracellular and 20 
plasma trough concentrations of LPV in 38 patients receiving LPV/RTV based 21 
regimen. They found that trough intracellular concentrations of LPV at week 4 were 22 
significantly higher (12.7 µg/mL) in patients achieving virological success before 23 
week 4 than in others (4.8 µg/mL) (P<0.0002). Similarly intracellular concentrations of 24 
LPV at week 24 were significantly higher (10.5 µg/mL) in patients achieving 25 
virological success before week 24 than in others (4.6 µg/mL) (P<0.002).[88] 26 
Virological success was also significantly associated with higher plasma through 27 
concentration at week 4 (P=10-5) and 24 (P=0.05) and with the genotype inhibitory 28 
quotient at week 4 (P=10-6) and 24 (P=0.0004). In a multivariate analysis of 29 
virological success at week 24, the authors found the effect of baseline LPV 30 
mutations, plasma concentration at week 4 and intracellular concentration at week 31 
24. The authors defined thresholds of 4 µg/mL and 8 µg/mL for plasma and 32 
intracellular concentration, respectively; they suggested combining plasma and 33 
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intracellular concentration of LPV for therapeutic drug monitoring. The authors 1 
derived cellular accumulation ratio but it was not used in the analysis of link with 2 
efficacy. 3 
The cross-sectional study by Chaillou et al.,[79] included 49 patients with antiretroviral 4 
combinations containing various protease inhibitors. The first objective was to study 5 
the relationship between MDR-1 gene expression and intracellular PI concentrations 6 
and then to evaluate the correlation of PI intracellular concentrations with virological 7 
response. Efficacy was defined as undetectable HIV RNA load (<40 cp/mL) at day of 8 
study. As various PIs were analyzed, to normalize concentrations authors studied the 9 
influence of the ratio of intracellular to plasma concentrations that they defined as 10 
accumulation but which is not a measure showing the amount of drug in body. They 11 
did not found any significant correlation on the main PI. The only parameter 12 
significantly linked with efficacy was the intracellular presence of RTV (P=0.04). For 13 
the 19 patients receiving RTV as a booster, patients with undetectable HIV viral load 14 
had significantly higher RTV intracellular accumulation than patients with detectable 15 
HIV RNA (P=0.029).  16 
In conclusion, in prospective studies well designed and with a reasonnable number of 17 
patients, all authors found a significant correlation between virological efficacy and 18 
intracellular concentrations of NRTIs with no influence of plasma concentration. For 19 
PIs, there is only one well-designed prospective trial on LPV, which found both the 20 
influence of trough plasma and intracellular concentrations at different week after 21 
treatment initiation. From these results, it is difficult to know whether the primary 22 
association is with plasma or intracellular concentrations. These findings obtained in 23 
only 38 patients should be confirmed by other studies. 24 
 25 
5.4 Relationship between intracellular concentrations and toxicity  26 
ARVs are known to produce important adverse effects which are the main drawback 27 
of HAART.[135] The toxicity related to ARVs is indeed an important cause of poor 28 
compliance, which is in return the main cause of treatment failure.[136] Besides, a viral 29 
rebound can be associated to the acquisition of mutation resistances by the virus, 30 
which can critically penalize the choice of the subsequent therapeutic strategy.[137-139] 31 
Most toxicities displayed by ARVs are typical of a pharmacological class excepted for 32 
NRTIs which trend to have their own toxicities. For instance, PIs are known to induce 33 
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digestive troubles and metabolic disorders, such as hyperlipidaemia, insulin 1 
resistance, diabetes mellitus, peripheral lipodystrophy, central adiposity[140-143]. NRTIs 2 
can be responsible for lipodystrophy[144], neuropathy[145] (ddI, d4T), myopathy[146], 3 
pancreatitis[147] (ddI,d4T), anaemia and neutropenia[148],(ZDV), renal impairment and 4 
fanconi syndrome[149] (TFV), hepatic steatosis, and lactic acidosis[144]; whereas 5 
NNRTIs can provide neuropsychological disorders for EFV[150] and skin or hepatic 6 
toxicity for NVP[151-153]. 7 
To date, the mechanisms leading to these toxicities are not perfectly understood, but, 8 
the main hypotheses highly suggest interferences with some cellular endogenous 9 
processes. For example, PIs could alter adipose tissue and lipid metabolism by 10 
inhibiting the heterodimeric nuclear receptor complex composed of peroxisome 11 
proliferator activated receptor γ and the retinoid X receptor, the cellular retinoic acid-12 
binding protein, and the synthesis of cis-9-retinoic acid.[154] PIs could also inhibit the 13 
degradation of the sterol element-binding proteins which regulate the transcription of 14 
the LDL receptor gene.[155, 156] Diabetes mellitus induced by PIs could be secondary 15 
to the direct inhibition of GLUT4, a transporter that mediates the cellular uptake of 16 
glucose stimulated by insulin.[157] Similarly, adverse effects due to NRTIs are thought 17 
to be related to michondrial damages, which are a consequence of NRTIs ability to 18 
inhibit the mitochondrial DNA polymerase.[158] 19 
Despite these elements, the possible relationship between intracellular concentration 20 
of ARVs and their related toxicity was to date investigated for four molecules (ZDV, 21 
3TC, TDF and EFV) only. 22 
First, Stretcher et al.,[132] evaluated in 13 naïve patients if the intracellular 23 
concentration of ZDV-P in PBMCs was related to some markers of ZDV-induced 24 
toxicity. A negative correlation was found between intracellular ZDV-P and the 25 
decrease in haemoglobin from its baseline level. It is noteworthy that the authors did 26 
not find in this study a significant correlation between plasma ZDV and intracellular 27 
ZDV-P, and did not investigate the possible relationship between plasma ZDV and 28 
haemoglobin decrease. However, other studies evidenced an association between 29 
plasma ZDV and anaemia[159, 160], so the relative strength of the association between 30 
haemoglobin decrease and plasma ZDV compared to intracellular ZDV-P is still 31 
unknown. A different result was nevertheless found in both adults and children. 32 
Indeed, in a study performed by Anderson et al.,[8] on 33 naïve adult patients 33 
receiving a ZDV-3TC-IDV regimen, no difference in the intracellular concentrations of 34 
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ZDV-TP and 3TC-TP was observed between the 14 patients who experienced at 1 
least a grade I biological event and the 19 patients who did not. A similar result was 2 
found in 49 neonates, as the proportion of observed haematological toxicities was not 3 
related to the intracellular concentrations of ZDV-TP and 3TC-TP.[99] However, 4 
differences between the pharmacokinetic criteria and the pharmacodynamic 5 
endpoints used (see table IV[8, 90, 99, 132]) might explain the inconsistency between 6 
these studies. There are also in vitro data suggesting ZDV-MP is the culprit of ZDV-7 
related anemia[161], so toxicity relationships with ZDV-TP may not be relevant. 8 
Among NNRTIs, in a study performed on 55 patients, Rotger at al.,[90] found a 9 
significant correlation between the intracellular concentration of EFV and the risk of 10 
mood disorders. No significant correlation was found with the risk of sleep disorders 11 
and fatigue. In contrast with other studies[162, 163], no significant association was 12 
observed between the plasma concentration of EFV and the neuropsychological 13 
trouble that were investigated. Once again, methodological differences penalize the 14 
comparison between studies. 15 
Last, Izzedine et al.,[64] found, without measuring the intracellular concentration of 16 
TFV-DP, that the risk to develop a renal proximal tubulopathy with TDF-containing 17 
treatments was significantly associated with genetic variants in the gene coding for 18 
MRP2, a transporter involved in TVF efflux from tubular cells to the urine. Since 19 
these variants are thought to be associated with a reduced activity of the transporter, 20 
this result could indicate that an accumulation in the tubular cell due to an altered 21 
MRP2-based efflux might be responsible for TDF-induced toxicity.[64] However, for 22 
obvious reasons, TFV concentration in the tubular cells could not be investigated, so 23 
this mechanistic explanation remains speculative, as are the role of mitochondria and 24 
TFV-DP in TDF toxicity. 25 
More generally, the impossibility to investigate cellular concentration of ARVs in the 26 
tissues targeted by their toxicity is a major weakness of these studies. However, it is 27 
interesting to note the neuropsychological effect of efavirenz or the anaemia induced 28 
by ZDV are not explained by the diffusion of these compounds to the PBMCs. 29 
Significant correlations indicate that concentration in PBMCs possibly reflects the 30 
diffusion of these drugs to other tissues like central nervous system or bone morrow. 31 
Measuring the concentrations of ARVs in PBMCs could therefore be an interesting 32 
tool to predict and consequently to prevent the appearance of toxicities related to 33 
HAART in a clinical setting. Further studies are therefore warranted to validate 34 
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PBMCs as a reliable model for investigating the relationship between the intracellular 1 
concentration of ARVs and their toxicity. 2 
 3 
6 Conclusion 4 
In conclusion, intracellular concentrations of ARVs play a major role in their efficacy 5 
and toxicity and are influenced by numerous factors. Although measurement of 6 
intracellular concentrations needs standardisation, this review demonstrates that 7 
relationships between intracellular concentrations of ARVs and their efficacy have 8 
been evidenced. Such relationships should be interpreted with caution as intracellular 9 
concentrations reflect the total amount of drug within the cell and not the effective 10 
unbound fraction. The number of clinical studies in that area is however rather 11 
limited, most studies being small and not always adequately designed. Improved 12 
techniques measuring relevant intracellular concentrations, improved knowledge on 13 
which cells would be the best surrogate marker on antiretroviral therapy including 14 
reservoirs as well as larger and prospectively designed clinical studies are needed to 15 
further investigate the links between intracellular concentrations and clinical 16 
endpoints.  17 
 18 
 19 
20 
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Tables 1 
Table I. Summary of pharmacokinetics parameters of available antiretroviral drugs adapted from [6, 8-13] 2 
 3 
 
 Bioavailability (%) tmax (h) Protein Binding (%) Elimination Pathway Plasma  t1/2 (h) 
Intracellular 
t1/2 (h) 
Entry Inhibitors 
Enfuvirtide  T20 70 (SC) 7 97 Peptidases -> amino acids 3 - 8  
Maraviroc  25-35% 2 76 25% renal + CYP3A 13  
Nucleosidic Reverse Trancriptase Inhibitors (NRTI) 
Zidovudine ZDV 60 1 20 20% renal + 80% glucuronidation UGT2B7 
1 - 1.5 7-11 
Didanosine ddI 40 1 < 5 50% renal 1-2 15 - 20 
Stavudine d4T 80 1 < 5 80% renal 1 - 1.5 7 
Lamivudine 3TC 80 1 < 5 80% renal 2-3 22 
Abacavir ABC 75 1 49 < 5% renal + liver biotransformation 
0,8 - 1,5 21 
Tenofovir TFV 40 2-3 < 10 80% renal 14 150-180 
Emtricitabine FTC 90 1 < 5 80% renal 9 39 
Non Nucleosidic Reverse Trancriptase Inhibitors (NNRTI) 
Efavirenz EFV 50 2-5 99.5 < 1% renal + CYP2B6 50  
Nevirapine NVP 90 4 60 < 15% renal + CYP2B6+3A4 25-30  
Integrase Inhibitor 
Raltegravir  ND 3 83 < 5% renal + UGT1A1 9  
Protease Inhibitors (PI) 
Saquinavir SQV 4-10 1-2 97 < 5% renal + CYP3A 5  
Indinavir IDV 60 1 60 10% renal + CYP3A 1.5 - 2 2 
Ritonavir RTV 70 3 99 < 5% renal + CYP3A 3-5  
Nelfinavir NFV 60-80 3 98 <5% renal + CYP3A 5-6  
Lopinavir/r LPV/r ND 5 99 < 5% renal + CYP3A 5-6  
Amprenavir APV 30-90 2 90 < 5% renal + CYP3A 7-12  
Atazanavir ATV ND 2 86 < 10% renal + CYP3A 7  
Darunavir DRV ND 1-4 94 < 5% renal + CYP3A 10 -15  
Tipranavir TPV ND 3 99 < 5% renal + CYP3A 6 (single dose)  
Abbreviations: SC: subcutaneous administration; r = ritonavir low-dose; CYP = P450 cytochrome; UGT=UDP-glucuronosyltransferase 4 
5 
 46
 1 
Table II. Intracellular pharmacokinetics of antiretrovirals and relationship with plasma pharmacokinetics 2 
 3 
Drug    Dosea Design Plasma and intracellular pharmacokinetics Correlation Ref 
  N 
Plasma  
(n / v) 
Intracellular 
(n / v) Parameters
b
 Plasma Intracellular Ratioc  
 
NRTI         
 
Zidovudine (ZDV)         
 
 
8 mg / kg  / day  49 1 / 2 1 / 2 Ctrough 0.00 – 1.29 µg/mL 16 – 385 fmol/106 cells NR Yes  
(R2 = NR) 
[99]
 
 
300 mg bid 14 8 / 1 3 / 3 AUC0-12h 1.8 – 1.7 h.µg/mL 1241 – 2172 h.fmol/106 cells NR No [81] 
 
300 mg bid 15 2 / 2 2 / 2 C1h 
C4h 
0.01 – 0.96 µg/mL 
0.01 – 1.08 µg/mL 
4 – 53 fmol/106 cells 
5.5 – 50.7 fmol/106 cells 
9 10-6  –  4.2 10-3 
9 10-6  –  3.4 10-3 
NR 
NR 
[87]
 
 
300 mg bid 
 
600 mg qd 
26 
 
 
27 
- 5 / 1 Ctrough 
 
Ctrough 
C24h 
- 
 
- 
- 
7.7 – 23.6 fmol/106 cells 
 
6.4 – 12.9 fmol/106 cells 
4.9 – 13.2 fmol/106 cells 
- 
 
- 
- 
- 
 
- 
- 
[91]
 
 
200 mg tid 38 7 / 2 4 / 2 AUC0-8h 
    Women 
    Men 
 
0.82 – 1.34 h.µg/mL 
0.88 – 1.35 h.µg/mL 
 
240 – 670 h.fmol/106 cells 
520 – 1150 h.fmol/106 cells 
 
NR 
NR 
 
NR 
NR 
[92]
 
 
300 mg tid 33 - 2 / 3  
 
Ctrough – C2h - 35 – 64 fmol/106 cells - - [72] 
 
300 mg bid 23 3 / 7 3 / 7 AUC0-2h 
    Week 0 
    Week 12 
    Week 48 
 
0.99 ±  0.71 h.µg/mL 
4.21 ± 1.52 h.µg/mL 
1.12 ±  0.41 h.µg/mL 
 
110 ±  80 h.fmol/106 cells 
130 ±  110 h.fmol/106 cells 
130 ±  120 h.fmol/106 cells 
NR Yes  
(R2 = NR) 
[83]
 
 
200 / 300 mg bidd 8 1-2 / 12 1-2 / 12 C2h – C8h 
CL/F 
0.18 – 0.32 µg/mL 
1.16 – 2.53 L/h/kg 
13.8 –  96.4 fmol/106 cells 
NR 
NR 
- 
No 
- 
[84]
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iv 1 / 2  mg / kg / he 28f >1 / 1 >1 / 1 Cdelivery  
CL/F 
0.19 –  3.66 µg/mL 
0.07 –  0.89 L/h/kg 
11 – 127 fmol/106 cells 
NR  
NR 
-
 
No 
- 
[93]
  
 
100 mg qd  
 
300 mg bid  
10 6 / 1 6 / 1 AUC0-12h 
 
AUC0-12h 
0.38 ±  0.13 h.µg/mL 
 
1.22 ±  0.21  h.µg/mL 
420 ±  420 fmol/106 cells 
 
610 ±  810 fmol/106 cells 
NR No [94]
 
 
500 mg qd 21 6 / 2 6 / 2 AUC0-8h 
   Week 4 
   Week ≥ 24 
 
0.71 ±  0.31 h.µg/mL 
0.79 ±  0.41 h.µg/mL 
 
3290 ±  970 h.fmol/106 cells 
2160 ± 1090 h.fmol/106 cells 
NR No [12]
 
 
500 mg qd 6 6 / 1 6 / 1 AUC0-8h 0.74 ± 0.27 h.µg/mL 4200 ±  2720 h.fmol/106 cells NR No [13] 
Didanosine (ddI)          
 
400 mg qd 16 - 4 / 1 Ctrough – C4h - 3.8 – 13.3 fmol/106 cells -   - [85] 
 
400 / 250 mg bid 28 1 / 1 1 / 1 C2.5h – C28.5h 0.00 – 0.16 µg/mL 0 – 23 fmol/106 cells NR No [11] 
Stavudine (d4T)         
 
 
40 mg bid 19 2 / 2 2 / 2 C1h  
C4h 
0.04 – 1.39 µg/mL 
0.04 – 0.73 µg/mL 
3 – 25 fmol/106 cells 
3.2 – 18.5 fmol/106 cells 
5 10-6  –  6.5 10-5 
7 10-6   – 2.4 10-4 
NR 
NR 
[87]
 
 
40 / 30 mg tid 28 1 / 1 1 / 1 C2.5h – C28.5h 0.04 – 0.67 µg/mL 0 – 99 fmol/106 cells NR Yes 
(R2 = 0.46) 
[11]
 
Lamivudine (3TC)         
 
 
300 mg qd  15 4 /1 4 / 1 AUC0-24h 
Cmax 
Ctrough 
3.71 –7.14 h.µg/mL 
1.66 – 2.59 µg/mL 
0.055 – 0.18  µg/Ml 
26910 – 80810 h.fmol/106 cells 
- 
6000 – 11460 fmol/106 cells 
- 
- 
- 
 
[105]
 
 
4 mg / kg / day 49 1 / 2 1 / 2 Ctrough 0.00 – 1.16 µg/mL 
 
570 – 38900 fmol/106 cells NR Yes 
(R2 = NR) 
[99]
 
 
150 mg bid 14 8 / 1 3 / 3 AUC0-12h 4.3 – 6.2 h.µg/mL 78.6 – 164.9 h.fmol/106 cells NR NR [81] 
 
150 mg bid 41 2 / 2 2 / 2 C1h  
C4h 
0.06 – 1.42 µg/mL 
0.02 – 1.81 µg/mL 
42 –  4579 fmol/106 cells 
200 – 10730 fmol/106 cells 
0.01 – 1.17 
0.06 – 41.58 
NR 
NR 
[87]
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300 mg qd 
 
 
150 mg bid 
25 
 
 
27 
- 4  / 1 Ctrough 
C24h 
 
Ctrough 
- 
- 
 
- 
0.7 106 – 2.4 106 fmol/106 cells 
1.0 106 – 2.5 106 fmol/106 cells 
 
0.7 106 – 4.0 106 fmol/106 cells 
- 
- 
 
- 
- 
- 
 
- 
[91]
 
 
300 mg qd 13 - 1-2 / 6 Ctrough - 7060 – 11600 fmol/106 cells - - [82] 
 
150 mg bid 32 - 2 / 3 Ctrough – C2h - 7252 – 9313 fmol/106 cells - - [72] 
 
150 mg bide 8 1-2 / 12 1-2 / 12 C2h – C8h 
 
CL/F 
0.43 – 0.69 µg/mL 
 
0.30 – 0.53 µg/mL 
2352 – 13024 fmol/106 cells 
 
NR 
NR 
 
- 
Yes 
(R² = 0.66) 
- 
[84]
 
Abacavir (ABC)         
 
 
300 mg bid 12 4 / 1 4 / 1 AUC0-24h 
Cmax 
Ctrough 
2.25 – 7.80 h.µg/mL 
0.95 – 3.72 µg/mL 
0.03 – 0.18 µg/mL 
656 – 2234 h.fmol/106 cells 
-  
98.3 – 472.8 fmol/106 cells 
- 
- 
- 
- 
- 
- 
[105]
 
 
600 mg qd 8 - 1-2 / 6 Ctrough - 88 – 200 fmol/106 cells - - [82] 
 
300 mg bid 9 8 / 1 4 / 1 Ctrough 
Cmax 
NQ 
1.48 – 2.35 µg/mL 
NQ 
- 
- 
- 
- 
- 
[86]
 
 
600 mg qd 5 - 8 / 1 Ctrough 
C1h 
C12h 
C14h –C16h 
C18h  
C20h 
C22h 
C24h 
- 
- 
- 
- 
- 
- 
- 
- 
 
127 – 575 fmol/106 cells 
107 – 670 fmol/106 cells 
188 fmol/106 cells 
101 – 548 fmol/106 cells 
113 – 648 fmol/106 cells 
80 – 660 fmol/106 cells 
105 – 201 fmol/106 cells 
62 – 354 fmol/106 cells 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
[101]
 
Tenofovir (TDF)         
 
 
300 mg qd 27 4 / 1 4 / 1 AUC0-24h 0.45 – 1.34 h.µg/mL 476.4 – 1386  h.fmol/106 cells -  [105] 
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Cmax 
Ctrough 
0.19 – 0.45 µg/mL 
0.03 – 0.119 µg/mL 
- 
116.5 – 376.5 fmol/106 cells 
- 
- 
 
300 mg qd 7 - 1-2 / 6 Ctrough - 85 – 110 fmol/106 cells - - [82] 
 
300 mg qd 8 - 4 / 1 Ctrough – C4h - 129 – 373 fmol/106 cells - - [85] 
 
300 mg qd 22 7 / 1 3 / 1 AUC0-24h 
C1h 
C4h 
C24h 
0.002 – 0.003 h.µg/mL 
NR 
NR 
0.052 – 0.068 h.µg/mL 
NR 
71 – 130 fmol/106 cells 
68 –  130 fmol/106 cells 
70 –  123 fmol/106 cells 
NR 
- 
- 
NR 
No 
- 
- 
NR 
[95]
 
Emtricitabine (FTC)         
 
 
25 mg bid 
 
 
200 mg qd 
 
 
100 mg bid 
 
 
100 mg qd 
 
 
200 mg bid 
9 
 
 
8 
 
 
8 
 
 
8 
 
 
8 
8 / 1 5-2 / 2 C1h 
C4h 
 
C1h 
C4h 
 
C1h 
C4h 
 
C1h 
C4h 
 
C1h 
C4h 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
0 – 1125 fmol/106 cells 
0 – 1450 fmol/106 cells 
 
0 – 2125 fmol/106 cells 
0 – 2250 fmol/106 cells 
 
0 – 4250 fmol/106 cells 
0 – 4625 fmol/106 cells 
 
0 – 2675 fmol/106 cells 
0 – 4000 fmol/106 cells 
 
0 – 4000 fmol/106 cells 
0 – 4100 fmol/106 cells 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
[10, 
100]
 
NNRTI         
 
Efavirenz (EFV)          
 
600 mg qd 49 1 / 2 1 / 2 C12h  
   Week 4 
   Week 24 
 
1.6 – 3.1 µg/mL 
1.4 – 2.5  µg/mL
 
 
2.8 – 11.5  µg/mL 
3.9 – 8.8 µg/mL 
 
2.2 – 5.4    
0.5 – 1.8
 
 
No 
No 
[96]
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600 mg qd 10 5 / 1 5 / 1 AUC0-24h 36.8 – 131.9 h.µg/mL 29.8 – 176.9 h.fmol/106 cells 0.7 – 3.3 Yes 
(R2 = 0.59) 
[34]
 
 
600 mg qd 55 1 / 1 1 / 1 AUC 7.9 –  63.1 h.µg/mL 6.3 – 794.3 h.µg/mL 
 
NR Yes 
(R² = 0.24) 
[90]
 
Nevirapine (NVP)          
 
200 mg bid 10 5 / 1 5 / 1 AUC0-12h 0.05 – 0.09 h.µg/mL 0.05 – 2.9  h.µg/mL 0 – 0.05 Yes 
(R2 = 0.62) 
[30]
 
 
400 mg bid 10 1 / 1 1 / 1 AUC 39.8 – 398.1 h.µg/mL 0.82 – 46.0  h.µg/mL NR NR [90]
 
PI          
 
Saquinavir (SQV)         
 
 
1600 mg qd 
 (+100 mg RTV)  
12 4 / 1 4 / 1 AUC0-24h 5.7 – 39.3 h.µg/mL 24.7 – 114.6 h.µg/mL 1.5 – 6.7 Yes 
(R2 = 0.63) 
[97]
 
 
1600 mg qd 
 (+100 mg RTV ) 
13 1 / 3 1 / 3 C24h 
    Week 2 
    Week 4 
 
0.04 – 1.43 µg/mL 
0.04 – 1.97 µg/mL 
 
0.15 – 0.79 µg/mL 
0.11 – 0.84 µg/mL 
1.1 – 8.7 Yes 
(R2 = 0.31) 
 
[89]
 
 
600 mg tid  
(+100 mg RTV bid) 
9 2 / 1 2 / 1 Ctrough 
Cmax 
NR 
NR 
NR 
NR 
0 – 50  
0 – 20   
NR 
NR 
[79]
 
Indinavir (IDV)         
 
 
800 mg tid 10 6 / 1 6 / 1 AUC0-8h 
Ctrough 
25.1 ±  4.2 h.µg/mL 
10.7 ±  1.3 µg/mL 
7.6 ±  1.0 h.µg/mL 
3.2 ±  0.7 µg/mL 
NR 
NR 
No 
 
[9]
 
 
800 mg bid  
(+100 mg RTV)  
 
400 mg bid 
 (+400 mg RTV)  
 
800 mg tid 
19 2 / 1 2 / 1 Ctrough 
Cmax 
 
Ctrough 
Cmax 
 
Ctrough 
Cmax 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
0 – 20  
1 – 5 
 
2.5 – 75  
2.5 – 13 
 
0 – 0  
0 – 7.5 
NR 
NR 
 
NR 
NR 
 
NR 
NR 
[79]
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Ritonavir (RTV)         
 
 
100 mg bid 11 14 / 1 4 / 1 AUC0-12h  2.7 –  4.1 h.µg/mL 9.1  –  14.2 h.µg/mL 3.2 – 7.7 NR [98] 
 
100 mg qd 12 4 / 1 4 / 1 AUC0-24h 1.5 – 14.6 h.µg/mL 3.2 – 13.7 h.µg/mL 0.8 – 4.2 No [97] 
 
400 / 100 mg bid 22 2 / 1 2 / 1 Ctrough NR NR 0 – 3.1  NR [79] 
Nelfinavir (NVF)         
 
 
1250 mg bid 12 5 / 1 5 / 1 AUC0-12h 
 
Ctrough 
5.6 – 50.8 h.µg/mL 
 
NR 
5.1 – 60.8 h.µg/mL 
 
NR 
NR 
 
NR 
Yes 
(R2 = 0.45) 
Yes 
[78]
 
 
750 mg tid 12 2 / 1 2 / 1 Ctrough 
Cmax 
NR 
NR 
NR 
NR 
0 – 37.5  
0 – 11.3  
NR 
NR 
[79]
 
Lopinavir (LPV)         
 
 
400 / 533 mg bid  
(+100 / 133 mg  RTV)   
38 1 / 2 1 / 2  Ctrough  
    Week 4 
   
    Week 24 
 
0.7 –  5.7 µg/mL 
 
0.7 –  7.7 
 
2.9 – 29.0  µg/mL 
 
0.1 – 27.5  (w)   
 
1.9 – 3.8 
 
1.3 – 3.1 
 
Yes  
(R² = 0.72) 
No 
[88]
 
 
400 mg bid  
(+100 mg RTV)  
11 14 / 1 4  / 1 AUC0-12h 61.8 –  82.8 h.µg/mL 63.1 –  113.8 h.µg/mL 0.7  2.  R [98] 
 1 
 2 
a
 All studies are performed at steady state 3 
b
 Values of the pharmacokinetics parameters as published in the original article: range, IQR or mean ± SD 4 
c
 Ratio defined by intracellular/plasma concentration 5 
d
 Individualized regimen after the second visit 6 
e
 Followed by a continuous infusion of 1 mg/kg/h until delivery 7 
f
 Pregnant women 8 
 9 
Abbreviations: AUC = area under the concentration time curve; bid = twice a day; Cmax = maximum concentration; CL/F = clearance; Ctrough = trough concentration; 10 
NNRTI = Non nucleoside analog inhibitors of reverse transcriptase; N = number of patients; n / v = number of samples per visit / number of visits; NRTI = Nucleoside 11 
 52
and nucleotide analog inhibitors of reverse transcriptase; NR = not reported in the article; NQ = not quantifiable; PI = protease inhibitors; qd = once a day; tid = three 1 
times a day. 2 
 3 
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Table III. Relationships between intracellular concentrations and efficacy of antiretroviral agents in patients 1 
 2 
Study 
 
Primary 
objective 
(yes/no) 
 
Type of trial 
Intracellular 
moieties Dosage regimen Patients 
Studied parameters 
from intracellular 
concentrations  
Efficacy criterion  Results
a
 
 
NRTI  
Moore et al.[87] 
Yes 
 
Substudy of 
clinical trial 
 
3TC-TP 
 
 
 
ZDV-TP 
 
 
d4T-TP 
 
 
3TC 150 mg  
+ ZDV 300 mg bid 
or 3TC 150 mg  
+ d4T 40 mg bid 
 
ZDV 300 mg 
+ 3TC 150 mg bid 
 
d4T 40 mg  
+ 3TC 150 mg bid 
 
39 naïve 
 
 
 
10 naïve 
 
 
15 naïve 
 
W28: Average of 1h 
and 4h conc. post dose 
Change between W0 and 
W24 in: 
(1) Log Plasma HIV RNA 
(2) CD4 cells 
 
 
(1) P < 0.02 
(2) NS 
 
 
(1) P < 0.02 
(2) NS 
 
(1) NS 
(2) NS 
 
Aweeka et 
al.[122] 
 
No 
 
Cross-
sectional 
analysis 
 
 
ZDV -TP Any regimen 
containing ZDV  
13 HCV or 
HBV co-
infected 
patients with 
stable 
regimen > 4 
weeks 
AUC (NCA) from 5  
samples:  pre dosing 
and 1,4 ,6 & 8h post 
dosing 
CD4 cell count at time of 
pharmacokinetic 
sampling 
NS 
Anderson et 
al.[8] 
Yes 
 
Substudy of 
clinical trial 
 
 
ZDV-TP 
 
 
 
 
 
3TC-TP 
ZDV 300 mg bid 
+ 3TC 150 mg bid 
+ IDV  800 mg tid 
or 
 Concentration-
Controlled  
ZDV-3TC-IDV 
regimen 
33 naïve 
Median conc. above 
threshold (yes/no) 
from samples 2h post 
dose at W2, 28 and 56 
and at 2 to 8 h  post 
dose at 9 visits from 
W8 to W80 
 
Thresholds: 
ZDV-TP:  30 fmol/106 
3TC-TP:  7017 fmol/106  
(1) Time to reach less 
than 50cp/mL of HIV RNA 
(2) Undetectable HIV 
RNA (< 50 cp/mL) at W24  
and W52 
(3) Time to loss of 
virological response in 
patients achieving 
undetectable 
(4) CD4 level at W24 and 
W48 
(1) P = 0.01 
(2) W24: P = 0.009 
      W52: NS 
(3) P = 0.02 
(4) NS 
 
 
(1) P = 0.02 
(2) W24: P = 0.002 
      W52: P = 0.0008 
(3) P = 0.002 
(4) NS 
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Fletcher et 
al.[84] 
 
Yes 
 
 Substudy of 
clinical trial  
 
ZDV-TP 
 
 
 
 
3TC-TP 
ZDV 300 mg bid 
+ 3TC 150 mg bid 
+ IDV  800 mg tid 
or 
 Concentration-
Controlled  
ZDV-3TC-IDV  
regimen 
8 naïve 
Median conc. 
 from samples 2h post 
dose at W2, 28 and 56 
and at 2 to 8 h  post 
dose at 9 visits from 
W8 to W80 
Change between W0 and 
W24 in 
(1) log HIV RNA 
(2) CD4 cell 
 
(1) P = 0.03 
(2) P = 0.001 
 
 
(1)  P = 0.003 
(2)  NS 
 
Stretcher et 
al.[132] 
Yes 
 
PK trial 
ZDV-P 
ZDV only: 
800 mg /day 
 100mg every 4h 
while awake 
21 naïve of 
ZDV 
AUC (NCA) from 6  
samples:  pre dosing 
and 1, 2, 4, 6 & 8h post 
dosing at W4 and 
>W24 
Change between W0 and 
W4 or  W0 and W24 of 
(1) % CD4 
(2) CD4 / CD8 ratio 
 
(1) W4: P = 0.029 
             W24: NS 
(2) W4: P = 0.028 
             W24: NS 
PI 
Lamotte et 
al.[89] 
No 
 
Secondary 
objective of 
clinical trial 
SQV  
SQV1600 mg 
+ RTV 100 mg qd 
+ 2 or 3 
NRTI/NNRTI 
13 naïve Ctrough (24h post dose) 
at W2, W4 or W12  
Change in Plasma HIV 
RNA between W0 and 
W12 
NS for all dates of 
trough measurements 
Breilh et al.[88] 
Yes 
 
Observationa
l study 
 
LPV 
LPV 400 mg 
+ RTV 100 mg bid 
+ 2 or 3 
NRTI/NNRTI 
38 naïve of 
LPV 
Ctrough (12h post dose) 
at W4 and W24 
 
Virological success:  
(1) HIV RNA < 50 cp/mL 
before W4  
(2) HIV RNA < 50 cp/mL 
before W4 and during all 
follow up until W24 
 
(1) P < 0.0002 
(2) P < 0.002 
Chaillou et 
al.[79] 
No 
 
Secondary 
objective 
Cross-
sectional trial  
 
NFV, IDV, 
APV, SQV, 
RTV 
NFV 750 mg tid 
or  IDV 800 mg tid 
or APV 1200 mg 
bid 
or IDV 800 mg + 
RTV 100 mg bid 
or SQV 600mg + 
RTV 100mg bid 
or APV 600 mg + 
RTV 100 mg bid 
or IDV 400 mg + 
RTV 400 mg bid 
+ 2 or 3 
NRTI/NNRTI 
49 
experienced 
patients 
Ratio of intracellular to 
plasma Ctrough and Cmax 
(1.5 to 3 h post dose) at 
day of study: 
(1) main PI 
(2) RTV 
 
 
Undetectable  HIV RNA 
(<40 cp/mL) at day of 
study  
 
(1) NS for PI ratio  
(2) P = 0.04 for 
presence of 
intracellular 
RTV 
  P = 0.029 with        
RTV ratio in 28  
patients 
receiving RTV 
 1 
a
  Significant results always associated better efficacy with higher intracellular concentrations 2 
 55
Abbreviations: APV = amprenavir; AUC = area under the concentration time curve; bid = twice a day;  Cmax = maximum concentration; Ctrough = trough 1 
concentration; d4T = stavudine; d4T-TP = stavudine triphosphate; IDV = indinavir; LPV = lopinavir ; NCA= non compartmental analysis; NFV = nelfinavir; 2 
NRTI = Nucleoside and nucleotide analog inhibitors of reverse transcriptase; NNRTI = Non nucleoside analog inhibitors of reverse transcriptase; NS = non-3 
significant ; PI = protease inhibitors; qd = once a day ; PK =  pharmacokinetic; RTV = ritonavir ; SQV =  saquinavir; tid = three times a day; ZDV = zidovudine; 4 
ZDV-P= total zidovudine phosphates; ZDV-TP = zidovudine triphosphate; 3TC = lamivudine ; 3TC -TP= lamivudine triphosphate; W = week.   5 
 6 
7 
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Table IV. Relationships between intracellular concentrations and toxicity of antiretroviral agents in patients 1 
 2 
Study  Primary objective 
Intracellular 
moieties Dosage regimen Patients 
Studied parameters from 
intracellular concentrations Toxicity criterion 
Resultsa 
 
NRTI  
 Anderson et 
al.[8] 
Yes 
 
Substudy of 
clinical trial 
 
 
ZDV-TP 
 
 
 
 
 
3TC-TP 
ZDV 300 mg bid 
+ 3TC 150 mg bid 
+ IDV  800 mg tid 
or 
 Concentration-
Controlled  
ZDV-3TC-IDV 
regimen 
33 naïve 
Median conc. above 
threshold (yes/no) 
from samples 2h post dose 
at W2, 28 and 56 and at 2 
to 8 hr  post dose at 9 visits 
from W8 to W80 
 
Thresholds: 
ZDV-TP:  30 fmol/106 
3TC-TP:  7017 fmol/106  
Apparition of a grade I 
laboratory event 
(hemoglobin, absolute 
neutrophil count, aspartate, 
aminotransferase/alanine) 
 
 
 
 
 
NS 
Stretcher et 
al.[132] 
Yes 
 
PK trial 
ZDV-P 
ZDV only: 
800 mg / day 
 100mg every 4 h 
while awake 
21 naïve 
AUC (NCA) from 6  
samples:  pre dosing and 1, 
2, 4, 6 & 8h post dosing at 
W4 and W24 
Change between W0 and 
W4 or  W0 and W24 of 
(1) neutrophils 
(2) red blood cells 
(3) hemoglobin 
 
(1) NS 
(2) NS 
(3) P = NS  
Durand-
Gasselin et 
al.[99] 
Yes 
 
PK trial 
ZDV-TP 
3TC-TP 
ZDV (8 mg/kg/day in 
4 daily doses) 
± 3TC(4 mg/kg/day in 
2 dayly doses) 
49 
neonates 
Single point concentration 
(time of sampling not 
reported) 
Proportions of the 
hematological toxicity grade 
between neonates with 
intracellular concentrations 
above or below the 
observed median 
 
 
NS 
NNRTI 
Rotger et 
al.[90] 
Yes 
 
PK Trial 
EFV 
EFV+ZDV+3TC 
EFV+ABC+3TC 
EFV+d4T+ddI 
+/- PI 
(doses not provided) 
55 
Intracellular AUC obtained 
by Bayesian estimation 
(number of samples per 
patient and sampling times 
not provided) 
Presence of grade I to IV of 
(1) sleep disorder 
(2) mood disorder 
(3) fatigue 
 
(1) NS 
(2) P = 0.02 
(3) NS 
 
 3 
a
   Significant results always associated increased risk of toxicity with higher intracellular concentrations 4 
 5 
Abbreviations: ABC = abacavir; AUC = area under the concentration time curve; bid = two times a day; tid = three times a day; ddI = didanosine; d4T = 6 
stavudine; EFV = efavirenz; IDV = indinavir; PI = protease inhibitors; PK = pharmacokinetic; NCA = non compartmental analysis; NS = non significant; 7 
ZDV = zidovudine; ZDV-P= total zidovudine phosphates; ZDV-TP = zidovudine triphosphate; 3TC = lamivudine; 3TC -TP= lamivudine triphosphate; W = 8 
week.9 
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 1 
Figure 1 
 
  
Figure 2 
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